FDA-approved1,2Evidence: Smaller human trialsGut and digestion

Secretin1

Also called ChiRhoStim, Human secretin1,2

Key takeaway

Secretin is a 27-amino-acid gut hormone that prompts the pancreas to release bicarbonate-rich fluid. ChiRhoStim contains a synthetic version identical to human secretin.1,2 It is approved as a diagnostic agent, not a treatment: its label covers tests of pancreatic function, testing for gastrin-producing tumors and helping doctors find the pancreatic duct openings during an endoscopic procedure (ERCP).1 In a randomized, placebo-controlled crossover study of 24 patients described in the label, the minor pancreatic duct was reached in 16 with secretin and 2 with placebo.1

Secretin at a glance

What it isA synthetic peptide hormone of 27 amino acids with the same sequence as natural human secretin, according to the ChiRhoStim label.1
FDA statusFDA-approved. It is approved for diagnostic use; Drugs@FDA lists ChiRhoStim, NDA 021256, with an original approval date of April 9, 2004. The cited label has no boxed warning.1,2
Human evidenceSmall diagnostic studies described in the label, including a randomized, placebo-controlled crossover study in 24 patients undergoing ERCP.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is secretin?

Secretin is a peptide hormone that the duodenum releases when stomach acid, fats or amino acids reach it. ChiRhoStim contains a synthetic form with the same 27-amino-acid sequence as the natural human hormone.1

In the United States it is the active ingredient of ChiRhoStim, approved under NDA 021256, according to Drugs@FDA.2

How does secretin work?

The label states that secretin binds to receptors on pancreatic duct cells and opens CFTR channels, so the pancreas secretes large volumes of fluid rich in bicarbonate.1

In people with gastrinoma, a gastrin-producing tumor, secretin raises blood gastrin, while healthy people show little or no change; the label states that this difference is the basis of the gastrinoma test.1

What do human studies show?

In a randomized, placebo-controlled crossover study of 24 patients with pancreas divisum undergoing ERCP, the minor duct was successfully entered in 16 of 24 with ChiRhoStim and 2 of 24 with placebo, according to the label.1

The label reports that all 21 patients with chronic pancreatitis in three crossover studies had low peak bicarbonate after secretin, while all 35 healthy people tested had normal values.1

In a crossover study of 6 patients with confirmed gastrinoma, all secretin products tested raised gastrin above the diagnostic threshold, and 12 healthy people tested negative, according to the label.1

What the evidence base contains

  • Controlled human trial A randomized, placebo-controlled crossover study in 24 patients with pancreas divisum undergoing ERCP, described in the label.1
  • Small, short, or incompletely reported human study Crossover studies comparing synthetic human and porcine secretin in 21 patients with chronic pancreatitis, and testing in 35 healthy people, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is secretin FDA-approved?

Yes, as a diagnostic agent. Drugs@FDA lists ChiRhoStim, application NDA 021256, with an original approval date of April 9, 2004.2

The ChiRhoStim label cited here (DailyMed version dated October 8, 2025, published November 17, 2025) states that it is indicated to stimulate pancreatic secretions to aid in diagnosing pancreatic exocrine dysfunction, to stimulate gastrin secretion to aid in diagnosing gastrinoma, and to help identify the pancreatic duct openings during ERCP.1

The label has no boxed warning and lists no contraindications. It warns that liver disease, earlier vagus nerve surgery, inflammatory bowel disease and some acid-lowering or anticholinergic drugs can distort test results.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Secretin is not among them.3,4

Timeline

  1. FDA approves ChiRhoStim, NDA 021256, according to Drugs@FDA.2
  2. DailyMed publishes the ChiRhoStim label version cited on this page.1

What is still unknown?

Fixed normal ranges: the label states that normal pancreatic responses vary between investigators and laboratories, and that each site should establish its own ranges.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Secretin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Secretin are a bounded selection, not every registration or paper about Secretin. For the years before Secretin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Secretin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Secretin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as ChiRhoStim for pancreatic and gastrinoma testing. The label describes small diagnostic studies, including a randomized, placebo-controlled crossover study of 24 patients undergoing ERCP. It is a diagnostic agent, not a treatment.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Secretin?

FDA-approved as ChiRhoStim for pancreatic and gastrinoma testing. The label describes small diagnostic studies, including a randomized, placebo-controlled crossover study of 24 patients undergoing ERCP. It is a diagnostic agent, not a treatment.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
19
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Secretin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

40Selected dated records
44Connected citations
19Populated source years2003–2026
3/4Record lanes present

Registered human studies

Trial composition

10 of 12 selected trial records include at least one phase value; 12 of 12 include a status value in the retained structured contract.

PhasesPhase 1 3Phase 2 3Phase 3 3Not applicable 2Phase 4 2
Status at observationCompleted 10Enrolling by invitation 1Recruiting 1

A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Review 20Research Support, Non-U.S. Gov't 12Research Support, N.I.H., Extramural 5Clinical Trial 4Randomized Controlled Trial 4Comparative Study 2Research Support, U.S. Gov't, P.H.S. 2Biography 1Historical Article 1Meta-Analysis 1Multicenter Study 1Portrait 1Research Support, U.S. Gov't, Non-P.H.S. 1Systematic Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
40

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 40 dated records

Research hub

Explore the Secretin evidence record

Open all 40 records →
40Dated records
3Evidence types
40Cited public sources
19Source years

Change ledger

Recently changed for Secretin

Open all 40 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00438906

PeptideScanner retained ClinicalTrials.gov record NCT00438906 at 2026-11-16T01:34:15.953Z. Its registry update date was 2021-06-18, and PeptideScanner's reviewed identity mapping was secretin.

PeptideScanner change date
November 16, 2026
Cited source date
June 18, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01087801

PeptideScanner retained ClinicalTrials.gov record NCT01087801 at 2026-11-16T01:34:15.953Z. Its registry update date was 2011-12-06, and PeptideScanner's reviewed identity mapping was secretin.

PeptideScanner change date
November 16, 2026
Cited source date
December 6, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01134848

PeptideScanner retained ClinicalTrials.gov record NCT01134848 at 2026-11-16T01:34:15.953Z. Its registry update date was 2010-06-02, and PeptideScanner's reviewed identity mapping was secretin.

PeptideScanner change date
November 16, 2026
Cited source date
June 2, 2010
Evidence lane
Clinical trials

Official-source collections

Source records for Secretin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors.The Journal of biological chemistry · 2025 07 09
  2. Secretin: a hormone for HCO3- homeostasis.Pflugers Archiv : European journal of physiology · 2024 01 15
  3. Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental development and preeclampsia.Frontiers in cell and developmental biology · 2022 09 14
Explore all selected literature →
ClinicalTrials.gov12

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT02000089Registry update October 22, 2026 · current at observation
  2. NCT05659147Registry update March 18, 2026 · current at observation
  3. NCT03404661Registry update June 6, 2023 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span August 18, 2003 to November 1, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 40

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Secretin: a hormone for HCO3- homeostasis.↗

    PubMed lists PMID 38221598 in Pflugers Archiv : European journal of physiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-15 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02000089↗

    PeptideScanner retained ClinicalTrials.gov record NCT02000089 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was secretin.↗

  3. Literature metadata

    Secretin as a treatment for autism: a review of the evidence.↗

    PubMed lists PMID 15628608 in Journal of autism and developmental disorders as Journal Article, Meta-Analysis, Review, with publication-date metadata of 2004-10 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05659147↗

    PeptideScanner retained ClinicalTrials.gov record NCT05659147 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-03-18, and PeptideScanner's reviewed identity mapping was secretin.↗

  5. Literature metadata

    Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors.↗

    PubMed lists PMID 40645521 in The Journal of biological chemistry as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-09 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    A systematic review of secretin for children with autism spectrum disorders.↗

    PubMed lists PMID 21464196 in Pediatrics as Journal Article, Research Support, N.I.H., Extramural, Systematic Review, with publication-date metadata of 2011-04-04 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT03404661↗

    PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.↗

  8. Literature metadata

    Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental development and preeclampsia.↗

    PubMed lists PMID 36187484 in Frontiers in cell and developmental biology as Journal Article, Review, with publication-date metadata of 2022-09-14 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    The role of secretin in the cerebellum.↗

    PubMed lists PMID 16527763 in Cerebellum (London, England) as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury.↗

    PubMed lists PMID 32737904 in Hepatology (Baltimore, Md.) as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review, with publication-date metadata of 2020-11-19 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    The physiological roles of secretin and its receptor.↗

    PubMed lists PMID 25332973 in Annals of translational medicine as Journal Article, Review, with publication-date metadata of 2013-10 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Consequences of splice variation on Secretin family G protein-coupled receptor function.↗

    PubMed lists PMID 21718310 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    CHIRHOSTIM (human secretin) for injection · SPL version 20251008 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: CHIRHOSTIM (secretin synthetic human), NDA 021256 · original approval April 9, 2004 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026